Last reviewed · How we verify
F-18 Fluorodeoxyglucose
F-18 Fluorodeoxyglucose, marketed by Boston Children's Hospital, is a radiopharmaceutical agent with a key composition patent expiring in 2028. The drug's primary strength lies in its established market presence and widespread use in diagnostic imaging. The primary risk is the potential increase in competition following the patent expiry in 2028.
At a glance
| Generic name | F-18 Fluorodeoxyglucose |
|---|---|
| Also known as | FDG |
| Sponsor | Boston Children's Hospital |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Therapy Adapted for High Risk and Low Risk HIV-Associated Anal Cancer (PHASE2)
- Testing Lutetium Lu 177 Dotatate in Patients With Somatostatin Receptor Positive Advanced Bronchial Neuroendocrine Tumors (PHASE2)
- Testing Immunotherapy Versus Observation in Patients With HPV Throat Cancer (PHASE3)
- Entinostat in Combination With Aldesleukin in Treating Patients With Metastatic Kidney Cancer (PHASE1, PHASE2)
- Testing the Investigational Medication Combination of Teclistamab and Pomalidomide Compared to the Usual Treatment (Carfilzomib, Pomalidomide, and Dexamethasone) for Patients With Multiple Myeloma Who Have Relapsed Shortly After Treatment (PHASE1, PHASE2)
- Comparing the Effectiveness of the Immunotherapy Agents Rituximab or Mosunetuzumab in Patients With Nodular Lymphocyte-Predominant Hodgkin Lymphoma, NORM Trial (PHASE2)
- Reliability of the Human Brain Connectome (EARLY_PHASE1)
- Testing the Addition of M3814 (Peposertib) to Radiation Therapy for Patients With Advanced Head and Neck Cancer Who Cannot Take Cisplatin (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- F-18 Fluorodeoxyglucose CI brief — competitive landscape report
- F-18 Fluorodeoxyglucose updates RSS · CI watch RSS
- Boston Children's Hospital portfolio CI